Publisher Summary At present there is no effective therapy for the majority of the patients who have chronic Chagas disease in the indeterminate (70–80%) and determinate (10–20%) periods. In the acquired acute period, 70% of the cases are cured, and in newborn and suckling children with congenital Chagas disease, a 98% cure is obtained. In the chronic acquired cases, cures reach 20% and improvement of cardiopathy, 50% (with itraconazole). New drugs are needed with high efficacy and without secondary effects, especially to treat chronic cases. In the last few years no new drugs have been developed against T. cruzi that can be applied to humans. This is due to the lack of interest of the big pharmaceutical companies to develop new drugs with low returns. The people with Chagas disease have low economic resources. Chagas disease is one of the most “neglected diseases,” and for this reason, without interest.